Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.

Autor: Ler LD; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.; NUS Graduate School for Integrative Sciences and Engineering, 28 Medical Drive, Singapore 117456, Singapore., Ghosh S; Program in Cardiovascular and Metabolic Disorders, Duke-NUS Medical School, Singapore 169857, Singapore.; Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore., Chai X; Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore., Thike AA; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Heng HL; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Siew EY; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Dey S; Cancer Science Institute of Singapore, National University of Singapore, Centre for Life Sciences, Singapore 117456, Singapore., Koh LK; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Lim JQ; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Lim WK; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Myint SS; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Loh JL; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Ong P; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Sam XX; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Huang D; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Lim T; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Tan PH; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Nagarajan S; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Cheng CW; Department of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore., Ho H; Department of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore., Ng LG; Department of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore., Yuen J; Department of Urology, Singapore General Hospital, Outram Road, Singapore 169608, Singapore., Lin PH; Division of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan., Chuang CK; Division of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan., Chang YH; Division of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan., Weng WH; Department of Chemical Engineering and Biotechnology and Graduate Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan., Rozen SG; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.; Centre for Computational Biology, Duke-NUS Medical School, Singapore 169857, Singapore., Tan P; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Centre for Life Sciences, Singapore 117456, Singapore.; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 169610, Singapore.; Genome Institute of Singapore, 60 Biopolis Street Genome, Singapore 138672, Singapore., Creasy CL; Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA., Pang ST; Division of Urooncology, Department of Urology, Chang Gung University and Memorial Hospital at LinKou, TaoYuan, Taiwan. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw., McCabe MT; Cancer Epigenetics Discovery Performance Unit, Oncology R&D, GlaxoSmithKline, 1250 South Collegeville Road, Collegeville, PA 19426, USA. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw., Poon SL; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore., Teh BT; Laboratory of Cancer Epigenome, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. teh.bin.tean@singhealth.com.sg songling.poon@gmail.com michael.t.mccabe@gsk.com jacobpang@adm.cgmh.org.tw.; Program in Cancer and Stem Cell Biology, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.; Cancer Science Institute of Singapore, National University of Singapore, Centre for Life Sciences, Singapore 117456, Singapore.; Institute of Molecular and Cell Biology, 61 Biopolis Drive, Proteos, #07-18, Singapore 138673, Singapore.

Publikováno v: Science translational medicine [Sci Transl Med] 2017 Feb 22; Vol. 9 (378).

Fumarate Hydratase-deficient Cell Line NCCFH1 as a New In Vitro Model of Hereditary Papillary Renal Cell Carcinoma Type 2.

Autor: Perrier-Trudova V; Ecole Pratique des Hautes Etudes, Paris and French National Institute of Health and Medical Research U753, Gustave Roussy Cancer Campus, Villejuif, France Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore., Huimin BW; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Republic of Singapore., Kongpetch S; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore., Huang D; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore., Ong P; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Republic of Singapore., Le Formal A; Ecole Pratique des Hautes Etudes, Paris and French National Institute of Health and Medical Research U753, Gustave Roussy Cancer Campus, Villejuif, France., Poon SL; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Republic of Singapore., Siew EY; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore., Myint SS; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore., Gad S; Ecole Pratique des Hautes Etudes, Paris and French National Institute of Health and Medical Research U753, Gustave Roussy Cancer Campus, Villejuif, France., Gardie B; French National Institute of Health and Medical Research U892 and French National Centre for Scientific Research 6299, Cancer Research Center Nantes-Angers, University of Nantes, Nantes, France., Couvé S; Ecole Pratique des Hautes Etudes, Paris and French National Institute of Health and Medical Research U753, Gustave Roussy Cancer Campus, Villejuif, France., Foong YM; Department of Biodevices and Diagnostics, Institute of Bioengineering and Nanotechnology, Singapore, Republic of Singapore., Choudhury Y; Department of Biodevices and Diagnostics, Institute of Bioengineering and Nanotechnology, Singapore, Republic of Singapore., Poh J; Department of Biodevices and Diagnostics, Institute of Bioengineering and Nanotechnology, Singapore, Republic of Singapore., Ong CK; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Republic of Singapore., Toh CK; Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Republic of Singapore., Ooi A; Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona, Arizona, AZ, U.S.A., Richard S; Ecole Pratique des Hautes Etudes, Paris and French National Institute of Health and Medical Research U753, Gustave Roussy Cancer Campus, Villejuif, France Faculty of Medicine, Paris-Sud University, Kremlin Bicêtre, Paris, France., Tan MH; Department of Biodevices and Diagnostics, Institute of Bioengineering and Nanotechnology, Singapore, Republic of Singapore Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Republic of Singapore minhan.tan@gmail.com teh.bin.tean@singhealth.com.sg., Teh BT; Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Republic of Singapore Division of Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Republic of Singapore minhan.tan@gmail.com teh.bin.tean@singhealth.com.sg.

Publikováno v: Anticancer research [Anticancer Res] 2015 Dec; Vol. 35 (12), pp. 6639-53.

Inhibition of placental growth factor in renal cell carcinoma.

Autor: Bessho H; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan hideji56@gmail.com., Wong B; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Huang D; Laboratory of Cancer Genetics, Van Andel Research Institute, Grand Rapids, MI, U.S.A., Siew EY; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Huang D; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Tan J; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Ong CK; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore., Tan SY; Department of Pathology, Singapore General Hospital, Singapore, Singapore., Matsumoto K; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Iwamura M; Department of Urology, Kitasato University School of Medicine, Kanagawa, Japan., Teh BT; Laboratory of Cancer Epigenome, National Cancer Centre Singapore, Singapore, Singapore Program in Cancer and Stem Cell Biology, Duke-NUS Graduate Medical School, Singapore, Singapore Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore.

Publikováno v: Anticancer research [Anticancer Res] 2015 Jan; Vol. 35 (1), pp. 531-41.

Genome-wide mutational signatures of aristolochic acid and its application as a screening tool.

Autor: Poon SL; NCCS-VARI Translational Research Laboratory, Division of Medical Sciences, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore., Pang ST, McPherson JR, Yu W, Huang KK, Guan P, Weng WH, Siew EY, Liu Y, Heng HL, Chong SC, Gan A, Tay ST, Lim WK, Cutcutache I, Huang D, Ler LD, Nairismägi ML, Lee MH, Chang YH, Yu KJ, Chan-On W, Li BK, Yuan YF, Qian CN, Ng KF, Wu CF, Hsu CL, Bunte RM, Stratton MR, Futreal PA, Sung WK, Chuang CK, Ong CK, Rozen SG, Tan P, Teh BT

Publikováno v: Science translational medicine [Sci Transl Med] 2013 Aug 07; Vol. 5 (197), pp. 197ra101.

Connecting the mechanisms of tumor sex differences with cancer therapy.

Autor: Li, Huan, Jiang, Weibo, Liu, Shui, Yang, Manshi, Chen, Siyuan, Pan, Yihan, Cui, Mengying

Publikováno v: Molecular & Cellular Biochemistry; Feb2024, Vol. 479 Issue 2, p213-231, 19p